NCT05207059 Healthy Early Life Moments in Singapore
| NCT ID | NCT05207059 |
| Status | Recruiting |
| Phase | — |
| Sponsor | KK Women's and Children's Hospital |
| Condition | Metabolic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-03-18 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2022-03-18 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess whether an integrated continuum of care from the preconception period, across maternity until the first 18 months of life, can promote maternal metabolic and mental health, as well as offspring health, among overweight and obese women.
Eligibility Criteria
Inclusion Criteria: 1. Women aged 21-40 years 2. BMI 25-40 kg/m2 3. Intention to reside in Singapore for the next 4 years 4. Chinese, Malay, Indian or any combination of these 3 ethnic groups 5. Planning to conceive within 1 year 6. Able to understand English 7. Able to provide written, informed consent Exclusion Criteria: 1. Currently pregnant 2. Known type 1 or type 2 diabetes 3. On any anticonvulsant medication in the past 1 month 4. On any oral steroid in the past 1 month (e.g. Prednisolone, Prednisone, Deltasone, Prelone, Methyl Prednisolone, Medrol, Hydrocortisone, Cortef, Dexamethasone, Decadron) 5. On any oral, implanted contraception or intrauterine contraceptive device (IUCD) in situ in the past 1 month 6. On any fertility medication (e.g. hormones injection, IVF treatments) other than Clomiphene/ Letrozole in the past 1 month 7. On HIV or Hepatitis B or C medication in the past 1 month.
Contact & Investigator
Jerry Chan, MB BCh BaO MA FRCOG PhD
PRINCIPAL INVESTIGATOR
KK Women's and Children's Hospital
Frequently Asked Questions
Who can join the NCT05207059 clinical trial?
This trial is open to female participants only, aged 21 Years or older, up to 40 Years, studying Metabolic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05207059 currently recruiting?
Yes, NCT05207059 is actively recruiting participants. Contact the research team at ng.xiang.wen@kkh.com.sg for enrollment information.
Where is the NCT05207059 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT05207059 clinical trial?
NCT05207059 is sponsored by KK Women's and Children's Hospital. The principal investigator is Jerry Chan, MB BCh BaO MA FRCOG PhD at KK Women's and Children's Hospital. The trial plans to enroll 500 participants.